3628 results for «328»

Filter By

3628 results

Most impactful trials in structural heart disease 2024/2025

30 Sep 2025 – From PCR Gulf Valves 2025

Delve into the most impactful structural heart disease trials shaping 2024 and 2025. This session addresses current dilemmas in TAVI, including early intervention and management of small annuli, evaluates evidence for transcatheter mitral and tricuspid valve repair, and identifies evidence gaps relevant to the region, providing...

Most impactful trials in structural heart disease 2024/2025

Expanding horizons with balloon-expandable TAVI - LIVE Case

12 Sep 2025 – From PCR Rio Valves 2025

A 76-year-old male with a history of abdominal and iliac stent grafts (2022), severe COPD, prostate cancer, and gastric ulcer presented with symptomatic severe aortic stenosis. CT and echocardiography showed a calcified bicuspid aortic valve with preserved LV function.

A 24.5 mm Myval valve was implanted without...

Expanding horizons with balloon-expandable TAVI - LIVE Case

Stent failure - LIVE Case

11 Oct 2025 – From AICT-AsiaPCR 2025

This educational session presents a live case from Apollo Hospitals, Chennai, focusing on stent failure management. It emphasizes the critical role of imaging in optimizing treatment for in-stent restenosis, discusses essential lesion preparation tools, and reviews various therapeutic options to improve patient care.

 LIVE Educational Case from...

Stent failure - LIVE

30 years of primary PCI – a tale of perseverance

16 May 2023

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

30 years of primary PCI – a tale of perseverance

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

The impact of COVID-19 pandemic on interventional cardiologists in training

23 Oct 2020

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

The impact of COVID-19 pandemic on interventional cardiologists in training

ACC 2019 Day 1: PARTNER 3, Evolut Low Risk Trial and Apple Heart Study

17 Mar 2019

Mirvat Al Asnag reports live on three late-breaking trials presented at ACC 2019: PARTNER 3, Evolut Low Risk Trial and the Apple Heart Study

Live from ACC 2019 Day 1: PARTNER 3, Evolut Low Risk Trial and Apple Heart Study

TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome

03 Sep 2025

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Author

Aaysha Cader
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
Didn’t find what you were looking for?